Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-1010
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol ; volume:27 ; number:1 ; day:23 ; month:10 ; year:2017 ; pages:1-6 ; date:12.2017
npj Primary care respiratory medicine ; 27, Heft 1 (23.10.2017), 1-6, 12.2017
- Urheber
-
Koch, Andrea
Watz, Henrik
Maleki-Yazdi, M. Reza
Bothner, Ulrich
Tetzlaff, Kay
Voß, Florian
McGarvey, Lorcan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41533-017-0059-1
- URN
-
urn:nbn:de:101:1-2019102019474030904943
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Koch, Andrea
- Watz, Henrik
- Maleki-Yazdi, M. Reza
- Bothner, Ulrich
- Tetzlaff, Kay
- Voß, Florian
- McGarvey, Lorcan
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Development of long-acting ARV’s
Formoterol : a long-acting β2-agonist for the management of asthma ; an international symposium, held during the joint meeting of SEP and SEPCR, London, 1990
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Creation of a long-acting nanoformulated dolutegravir
Long-Acting Reversible Contraception
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD